CardioMech performs the first in-person procedure using transcatheter mitral valve repair technology
CardioMech yesterday confirmed the completion of the first procedure with its Transcatheter Mitral Valve Repair (TMVR) technology.
The patient diagnosed with severe symptomatic degenerative mitral regurgitation (DMR) was evaluated by the multidisciplinary cardiac team at the Sanger Heart & Vascular Institute and, according to a report from Atrium Health, offered.
CardioMech’s Minneapolis-based transcatheter technology for transseptal chordal mitral valve repair is currently in an FDA-approved early feasibility study and is not yet commercially available in the United States or anywhere else in the world.
The procedure was performed in early September 2021 and was the first time CardioMech MVRS technology has been used on a human
“For over a decade we have been the leader and innovator in transcatheteric mitral valve therapy,” said Dr. Michael Rinaldi, interventional cardiologist and medical director of the Sanger Structural Heart Program. “This was such an exciting opportunity to participate in the very first human clinical trial of a technology that could prove to be an alternative therapy to other therapies we have worked with and developed.”
CardioMech has developed its catheter-based mitral valve repair technology to treat patients suffering from moderate to severe or severely symptomatic DMR due to prolapse or flail and offers therapy for artificial tendon placement to reduce or eliminate MR.
The procedure involves implanting artificial tendons with anchors at each end – one for the mitral valve leaflet and the other for the left ventricular wall – and then fitting the artificial tendons on a beating heart to reduce or eliminate regurgitation.
“This procedure allows the surgeon to pull down the limp mitral leaflet in real time as the valve opens and closes, and tries to return the valve to its natural shape,” said Rinaldi. If the procedure doesn’t work, “the surgeon can simply surgically repair the valve or add a catheter-based clip to further minimize leakage.”
Rinaldi noted that the procedure was “a complete win” and a clinical success as it reduced mitral valve leak from severe to easy. The next day the patient returned home.
âWhen it comes to patient care, we don’t just want to offer good care; we want to offer the best science-based medicine available, âsaid Rinaldi. âOur goal is to make the latest techniques and technologies available to our patients. For this reason, we continue to lead the way in these technologies through clinical studies. “